Abstract CT075: Phase 1a/1b dose-escalation study of efbalropendekin alfa (XmAb24306) as single-agent and with atezolizumab in solid tumors.

Ben Tran, Anna Spreafico, Daan G. Knapen, Do-Youn Oh, Erika Hamilton, Bridget P. Keenan, Saad A. Khan, Patricia LoRusso, Marwan Fakih, Michael Gordon, Jing Jing, Yanqiu Liu, Patrick Holder, Pranay Dogra, Whitney Kirschbrown, Vittal Shivva, Samuel Tracy, Sharareh Monemi, Shomyseh Sanjabi, Alexander Ungewickell, Caroline McCoach, Tae Won Kim. Abstract CT075: Phase 1a/1b dose-escalation study of efbalropendekin alfa (XmAb24306) as single-agent and with atezolizumab in solid tumors. Cancer Research. 2025 Apr 25; 85(8_Supplement_2):ct075-ct075.